Bicara Therapeutics Inc. Common Stock (BCAX) Earnings History
Annual and quarterly earnings data from 2022 to 2024
Loading earnings history...
BCAX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BCAX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
Download Data
Export BCAX earnings history in CSV or JSON format
Free sign-in required to download data
Bicara Therapeutics Inc. Common Stock (BCAX) Earnings Overview
As of May 8, 2026, Bicara Therapeutics Inc. Common Stock (BCAX) reported trailing twelve-month net income of -$122M, reflecting -25.0% year-over-year growth. The company earned $-2.23 per diluted share over the past four quarters.
Looking at the long-term picture, BCAX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$38M in fiscal 2022.
Bicara Therapeutics Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), TGTX ($462M net income, 72.6% margin), ACLX (-$229M net income, -1027.3% margin), BCAX has comparable earnings metrics. Compare BCAX vs IMVT →
BCAX Earnings vs Peers
Earnings metrics vs comparable public companies
BCAX Historical Earnings Data (2022–2024)
3 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$68M | -30.8% | -$82M | $-1.25 | - | - |
| 2023 | -$52M | -37.4% | -$40M | $-1.00 | - | - |
| 2022 | -$38M | - | -$38M | $-0.73 | - | - |
See BCAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCAX — Frequently Asked Questions
Quick answers to the most common questions about buying BCAX stock.
Is BCAX growing earnings?
BCAX EPS fell to $-2.23, with earnings declining -25.0%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-122M.
What are BCAX's profit margins?
Bicara Therapeutics Inc. Common Stock net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are BCAX's earnings?
BCAX earnings data spans 2022-2024. The declining earnings trend is -25.0% YoY. Historical data enables comparison across business cycles.